Reumatologia clinica最新文献_第4页

Erratum to Right ventriculoarterial coupling as a marker of subclinical myocardial damage in rheumatoid arthritis’ 右心室动脉偶联作为类风湿关节炎亚临床心肌损害标志物的错误。

Reumatologia clinica

Pub Date : 2025-10-01 DOI: 10.1016/j.reumae.2025.250178

Tomás Miranda-Aquino , Diego Alejandro Ramos-Aguas , Silvia Esmeralda Pérez-Topete , María del Socorro Cepeda-Rocha , Xochitl Citlalli Gómez-Gómez , Daniel Ochoa-Castillo , Sergio Cerpa-Cruz , Verónica González-Díaz , Christian González-Padilla , Jorge Eduardo Hernández-del Río

引用次数: 0

Association between hypothyroidism and elderly-onset rheumatoid arthritis: A cross-sectional study at national hospital in Peru 甲状腺功能减退与老年类风湿关节炎之间的关系：秘鲁国家医院的横断面研究

Reumatologia clinica

Pub Date : 2025-10-01 DOI: 10.1016/j.reumae.2025.501948

Paul J. Tejada-Llacsa , Vidia Lumbe Diaz , Carlos Diaz-Arocutipa

Objective

To determine the association between hypothyroidism and elderly-onset rheumatoid arthritis (EORA).

Methods

A cross-sectional study was performed including patients with rheumatoid arthritis at the Adolfo Guevara Velasco National Hospital, Cusco, Peru in 2024. The outcome was EORA, defined as disease onset after 60 years old. The exposure was a history of hypothyroidism, and the following covariates were considered: sex, smoking, family history of autoimmune disease in first-degree relatives, rheumatoid factor and anti-CCP levels. The association between hypothyroidism and EORA was assessed using prevalence ratios (PR) with their 95% confidence interval (CI), estimated by generalized linear models with a Poisson family, log link, and robust variance. A p-value <0.05 was considered statistically significant.

Results

A total of 133 patients were included, 14 (10.5%) of whom had EORA. The mean age was 55 ± 12.6 years and 90% were female. Only 8.3% of patients reported a history of hypothyroidism. Hypothyroidism was significantly associated with EORA (adjusted PR 9.03, 95% CI 3.17–26.68). Other factors associated with EORA were disease duration, smoking, the history of autoimmune disease in a first-degree relative, and rheumatoid factor.

Conclusions

A history of hypothyroidism was independently associated with EORA in patients with rheumatoid arthritis from Peru. Screening for hypothyroidism in EORA patients may enhance management and address autoimmune comorbidities.

目的探讨甲状腺功能减退与老年类风湿关节炎（EORA）的关系。方法对2024年在秘鲁库斯科阿道夫·格瓦拉·贝拉斯科国立医院就诊的类风湿性关节炎患者进行横断面研究。结果为EORA，定义为60岁以后发病。暴露为甲状腺功能减退史，考虑了以下协变量：性别、吸烟、一级亲属自身免疫性疾病家族史、类风湿因子和抗ccp水平。甲状腺功能减退和EORA之间的关系通过患病率（PR）及其95%置信区间（CI）进行评估，并通过泊松家族、对数关联和稳健方差的广义线性模型进行估计。p值<；0.05被认为具有统计学意义。结果共纳入133例患者，其中EORA患者14例（10.5%）。平均年龄55±12.6岁，女性占90%。仅有8.3%的患者报告有甲状腺功能减退病史。甲状腺功能减退与EORA显著相关（调整后的PR为9.03,95% CI为3.17-26.68）。与EORA相关的其他因素有病程、吸烟、一级亲属自身免疫性疾病史和类风湿因子。结论秘鲁类风湿关节炎患者甲状腺功能减退史与EORA独立相关。筛查EORA患者的甲状腺功能减退可以加强管理和解决自身免疫性合并症。

{"title":"Association between hypothyroidism and elderly-onset rheumatoid arthritis: A cross-sectional study at national hospital in Peru","authors":"Paul J. Tejada-Llacsa , Vidia Lumbe Diaz , Carlos Diaz-Arocutipa","doi":"10.1016/j.reumae.2025.501948","DOIUrl":"10.1016/j.reumae.2025.501948","url":null,"abstract":"<div><h3>Objective</h3><div>To determine the association between hypothyroidism and elderly-onset rheumatoid arthritis (EORA).</div></div><div><h3>Methods</h3><div>A cross-sectional study was performed including patients with rheumatoid arthritis at the Adolfo Guevara Velasco National Hospital, Cusco, Peru in 2024. The outcome was EORA, defined as disease onset after 60 years old. The exposure was a history of hypothyroidism, and the following covariates were considered: sex, smoking, family history of autoimmune disease in first-degree relatives, rheumatoid factor and anti-CCP levels. The association between hypothyroidism and EORA was assessed using prevalence ratios (PR) with their 95% confidence interval (CI), estimated by generalized linear models with a Poisson family, log link, and robust variance. A <em>p</em>-value <0.05 was considered statistically significant.</div></div><div><h3>Results</h3><div>A total of 133 patients were included, 14 (10.5%) of whom had EORA. The mean age was 55±12.6 years and 90% were female. Only 8.3% of patients reported a history of hypothyroidism. Hypothyroidism was significantly associated with EORA (adjusted PR 9.03, 95% CI 3.17–26.68). Other factors associated with EORA were disease duration, smoking, the history of autoimmune disease in a first-degree relative, and rheumatoid factor.</div></div><div><h3>Conclusions</h3><div>A history of hypothyroidism was independently associated with EORA in patients with rheumatoid arthritis from Peru. Screening for hypothyroidism in EORA patients may enhance management and address autoimmune comorbidities.</div></div>","PeriodicalId":94193,"journal":{"name":"Reumatologia clinica","volume":"21 8","pages":"Article 501948"},"PeriodicalIF":0.0,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145223508","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Rotator cuff tendinopathy is associated with increased activity score in rheumatoid arthritis 类风湿性关节炎患者肩袖肌腱病变与活动评分增高相关

Reumatologia clinica

Pub Date : 2025-10-01 DOI: 10.1016/j.reumae.2025.501947

Jorge Medina-Castillo , Rodrigo J. Castillo-de la Garza , David Vega-Morales , Jorge A. Esquivel-Valerio , Axel A. De León-Pérez , Lorenia De La Cruz-Becerra , Alondra Elizabeth Montoya-Montes , Lourdes Gil-Flores , Dionicio Ángel Galarza-Delgado

Introduction and objective

Rheumatoid arthritis (RA) is often accompanied by musculoskeletal (MS) symptoms, which can hinder the diagnosis of concurrent conditions like rotator cuff tendinopathy (RCT), the most common cause of shoulder pain. Undiagnosed RCT in patients with RA may be associated with higher disease activity scores. This study aimed to assess the difference in these scores between RA patients with and without RCT, considering ultrasound pathological findings.

Methods

We conducted a cross-sectional, observational, comparative study in patients with shoulder pain who met the 2010 ACR-EULAR classification criteria for RA between January 2022 and January 2023. The measurements of Disease Activity Score based on 28 joints using C-Reactive Protein (DAS28-CRP), Erythrocyte Sedimentation Rate (DAS28-ESR), and the Clinical Disease Activity Index (CDAI) were used to evaluate RA activity, while functional capacity was assessed using the Health Assessment Questionnaire Disability Index (HAQ-DI). The Disabilities of the Arm, Shoulder, and Hand questionnaire (DASHe) and shoulder ultrasound examination was performed to detect the presence or absence of RCT.

Results

Patients with RCT had greater mean scores on DAS28-CRP (5.23, 1.28 vs. 3.08, p < 0.001), and DAS 28-ESR (5.43, SD = 1.28 vs. 3.66, p < 0.001). VAS median scores were higher in the RCT group (70.00 vs. 2.00, p < 0.001). By ultrasound 12 patients (21%) had acromioclavicular synovitis. Glenohumeral and acromioclavicular arthrosis was found in both groups. No patients had arthritis in the glenohumeral joint.

Conclusion

RA patients with RCT have higher composite index and disease activity scores than those without RCT. An intentional RCT screening should be recommended for those with shoulder pain and elevated disease activity.

简介和目的类风湿性关节炎（RA）通常伴有肌肉骨骼（MS）症状，这可能会阻碍并发疾病的诊断，如肩袖肌腱病变（RCT），这是最常见的肩部疼痛原因。RA患者中未确诊的RCT可能与较高的疾病活动度评分相关。本研究旨在考虑超声病理结果，评估有和没有RCT的RA患者之间这些评分的差异。方法：我们对2022年1月至2023年1月期间符合2010年ACR-EULAR分类标准的肩痛患者进行了一项横断面、观察性、比较研究。采用c -反应蛋白（DAS28-CRP）、红细胞沉降率（DAS28-ESR）和临床疾病活动性指数（CDAI）对28个关节进行疾病活动性评分，评估RA活动性，采用健康评估问卷残疾指数（HAQ-DI）评估功能能力。通过手臂、肩膀和手的残疾问卷（DASHe）和肩部超声检查来检测是否存在RCT。结果RCT组患者在DAS28-CRP（5.23分，1.28比3.08分，p < 0.001）和DAS 28-ESR（5.43分，SD = 1.28比3.66,p < 0.001）上的平均得分更高。RCT组VAS中位评分较高（70.00 vs. 2.00, p < 0.001）。超声检查显示肩锁滑膜炎12例（21%）。两组患者均有肩关节和肩锁关节病变。没有患者有肩关节关节炎。结论RCT组ra患者的综合指数和疾病活动性评分均高于无RCT组。对于肩部疼痛和疾病活动度升高的患者，建议进行随机对照试验筛查。

{"title":"Rotator cuff tendinopathy is associated with increased activity score in rheumatoid arthritis","authors":"Jorge Medina-Castillo , Rodrigo J. Castillo-de la Garza , David Vega-Morales , Jorge A. Esquivel-Valerio , Axel A. De León-Pérez , Lorenia De La Cruz-Becerra , Alondra Elizabeth Montoya-Montes , Lourdes Gil-Flores , Dionicio Ángel Galarza-Delgado","doi":"10.1016/j.reumae.2025.501947","DOIUrl":"10.1016/j.reumae.2025.501947","url":null,"abstract":"<div><h3>Introduction and objective</h3><div>Rheumatoid arthritis (RA) is often accompanied by musculoskeletal (MS) symptoms, which can hinder the diagnosis of concurrent conditions like rotator cuff tendinopathy (RCT), the most common cause of shoulder pain. Undiagnosed RCT in patients with RA may be associated with higher disease activity scores. This study aimed to assess the difference in these scores between RA patients with and without RCT, considering ultrasound pathological findings.</div></div><div><h3>Methods</h3><div>We conducted a cross-sectional, observational, comparative study in patients with shoulder pain who met the 2010 ACR-EULAR classification criteria for RA between January 2022 and January 2023. The measurements of Disease Activity Score based on 28 joints using C-Reactive Protein (DAS28-CRP), Erythrocyte Sedimentation Rate (DAS28-ESR), and the Clinical Disease Activity Index (CDAI) were used to evaluate RA activity, while functional capacity was assessed using the Health Assessment Questionnaire Disability Index (HAQ-DI). The Disabilities of the Arm, Shoulder, and Hand questionnaire (DASHe) and shoulder ultrasound examination was performed to detect the presence or absence of RCT.</div></div><div><h3>Results</h3><div>Patients with RCT had greater mean scores on DAS28-CRP (5.23, 1.28 vs. 3.08, <em>p</em>    <0.001). VAS median scores were higher in the RCT group (70.00 vs. 2.00, <em>p</em>  <!-->0.001). By ultrasound 12 patients (21%) had acromioclavicular synovitis. Glenohumeral and acromioclavicular arthrosis was found in both groups. No patients had arthritis in the glenohumeral joint.</div></div><div><h3>Conclusion</h3><div>RA patients with RCT have higher composite index and disease activity scores than those without RCT. An intentional RCT screening should be recommended for those with shoulder pain and elevated disease activity.</div></div>","PeriodicalId":94193,"journal":{"name":"Reumatologia clinica","volume":"21 8","pages":"Article 501947"},"PeriodicalIF":0.0,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145223512","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Survival of first line biological and targeted synthetic disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis in Chile 智利类风湿关节炎患者一线生物和靶向合成疾病改善抗风湿药物的生存期

Reumatologia clinica

Pub Date : 2025-10-01 DOI: 10.1016/j.reumae.2025.501946

Marcos Cruces Olivar , Allan D. Burboa , Yolanda M. Gómez

Introduction

In Chile, patients with refractory rheumatoid arthritis (RA) are candidates for treatment with biologic and targeted synthetic disease-modifying anti-rheumatic drugs (b/tsDMARDs). Due to the cost and diversity of drugs currently available to treat RA, there is a greater need to evaluate their survival in the real world and mainly to provide local and national data.

Objectives

To describe the survival and cause of discontinuation/change of first line b/tsDMARDs in patients with active refractory RA at the rheumatology clinic of the Regional Hospital of Copiapó.

Materials and methods

Patients with refractory RA on first-line treatment with b/tsDMARDs were included. Data were obtained from the RA registry of patients from January 01, 2018, until July 31, 2023, and by reviewing medical records. Demographic and clinical characteristics of the patients, survival of b/tsDMARDs, and cause of discontinuation/change of therapy are described. Kaplan–Meier plots and log-rank tests were performed. Cox model was used to identify factors that affected treatment discontinuation.

Results

One hundred thirty patients met the selection criteria. Survival of the different treatments was calculated, excluding rituximab and tocilizumab due to n <10. There were no significant differences between the survival of the groups (anti-TNF, abatacept, tofacitinib), with p > 0.05. The mean survival time for b/tsDMARDs was 194 weeks. In this cohort, 34.62% (n = 45) of the patients had treatment discontinuation/change, with lack of efficacy representing 80%.

Conclusion

In this cohort of patients with RA, there were no statistically significant differences in survival after first-line treatment with b/tsDMARDs. The choice of initial therapy will depend on multiple clinical, demographic, economic and regulatory factors.

在智利，难治性类风湿关节炎（RA）患者是生物和靶向合成疾病修饰抗风湿药物（b/tsDMARDs）治疗的候选者。由于目前可用于治疗类风湿性关节炎的药物的成本和多样性，更需要评估它们在现实世界中的生存期，主要是提供地方和国家数据。目的了解Copiapó地区医院风湿科门诊活动性难治性RA患者b/ tsdmard一线停药/改变的生存期及原因。材料和方法纳入b/tsDMARDs一线治疗的难治性RA患者。数据来自2018年1月1日至2023年7月31日期间RA患者的注册表，并通过查看医疗记录获得。描述了患者的人口统计学和临床特征，b/tsDMARDs的生存以及停药/改变治疗的原因。Kaplan-Meier图和log-rank检验。采用Cox模型确定影响停药的因素。结果130例患者符合入选标准。计算不同治疗的生存期，不包括利妥昔单抗和托珠单抗，因为n <；10。抗肿瘤坏死因子组、阿巴接受组、托法替尼组的生存率差异无统计学意义，p > 0.05。b/tsDMARDs的平均生存时间为194周。在该队列中，34.62% （n = 45）的患者停药/改变治疗，80%的患者缺乏疗效。结论在这组RA患者中，b/tsDMARDs一线治疗后的生存率无统计学差异。初始治疗的选择将取决于多种临床、人口、经济和监管因素。

{"title":"Survival of first line biological and targeted synthetic disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis in Chile","authors":"Marcos Cruces Olivar , Allan D. Burboa , Yolanda M. Gómez","doi":"10.1016/j.reumae.2025.501946","DOIUrl":"10.1016/j.reumae.2025.501946","url":null,"abstract":"<div><h3>Introduction</h3><div>In Chile, patients with refractory rheumatoid arthritis (RA) are candidates for treatment with biologic and targeted synthetic disease-modifying anti-rheumatic drugs (b/tsDMARDs). Due to the cost and diversity of drugs currently available to treat RA, there is a greater need to evaluate their survival in the real world and mainly to provide local and national data.</div></div><div><h3>Objectives</h3><div>To describe the survival and cause of discontinuation/change of first line b/tsDMARDs in patients with active refractory RA at the rheumatology clinic of the Regional Hospital of Copiapó.</div></div><div><h3>Materials and methods</h3><div>Patients with refractory RA on first-line treatment with b/tsDMARDs were included. Data were obtained from the RA registry of patients from January 01, 2018, until July 31, 2023, and by reviewing medical records. Demographic and clinical characteristics of the patients, survival of b/tsDMARDs, and cause of discontinuation/change of therapy are described. Kaplan–Meier plots and log-rank tests were performed. Cox model was used to identify factors that affected treatment discontinuation.</div></div><div><h3>Results</h3><div>One hundred thirty patients met the selection criteria. Survival of the different treatments was calculated, excluding rituximab and tocilizumab due to <em>n</em> <10. There were no significant differences between the survival of the groups (anti-TNF, abatacept, tofacitinib), with <em>p</em>  =45) of the patients had treatment discontinuation/change, with lack of efficacy representing 80%.</div></div><div><h3>Conclusion</h3><div>In this cohort of patients with RA, there were no statistically significant differences in survival after first-line treatment with b/tsDMARDs. The choice of initial therapy will depend on multiple clinical, demographic, economic and regulatory factors.</div></div>","PeriodicalId":94193,"journal":{"name":"Reumatologia clinica","volume":"21 8","pages":"Article 501946"},"PeriodicalIF":0.0,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145223507","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Real life treatment in juvenile idiopathic arthritis: Is remission long lasting? 青少年特发性关节炎的现实生活治疗：缓解是持久的吗？

Reumatologia clinica

Pub Date : 2025-10-01 DOI: 10.1016/j.reumae.2025.501949

Laura Trives-Folguera, Ana Melissa Anzola, Indalecio Monteagudo-Saéz, Juan Carlos Nieto-González

Objectives

Juvenile idiopathic arthritis (JIA) is a chronic inflammatory disease that can cause pediatric disability. Achieving stable remission is the main objective to avoid disability. We evaluated remission survival in a cohort of patients with JIA and analyzed factors that might influence long lasting remission.

Methods

We designed an observational, retrospective and longitudinal study of JIA patients. Remission survival was determined from the first visit in clinical remission to the first flare after remission or the last visit recorded at the end of the study. Stable remission was defined as patients fulfilling the Wallace criteria during 18 months of the Covid pandemic. To compare the role of treatment on stable remission, we divided patients into three groups: without systemic treatment, treated with methotrexate only and treated with biologics.

Results

We included 82 JIA patients, 68.3% of whom were female and the median age of disease onset was 4.49 years old. There were no differences in the remission survival rates between JIA subgroups. Nearly 80% had maintained remission at 3 years and a high proportion of patients (68.3%) were still in remission after 5 years. Fifty-seven patients (69.5%) reached stable remission throughout 18 months of the Covid-19 pandemic. Stable remission was more likely in patients without systemic treatment (47.4%) (p = 0.015).

Conclusions

Remission survival was long-term in real life conditions, with nearly 80% of our patients maintaining stable remission after 3 years. Flares were more frequent in patients treated with methotrexate in monotherapy.

目的：小儿特发性关节炎（JIA）是一种可导致儿童残疾的慢性炎症性疾病。实现稳定的缓解是避免残疾的主要目标。我们评估了一组JIA患者的缓解生存期，并分析了可能影响长期缓解的因素。方法对JIA患者进行观察性、回顾性和纵向研究。从临床缓解的第一次就诊到缓解后的第一次发作或研究结束时记录的最后一次就诊，确定缓解期生存期。稳定缓解被定义为在新冠肺炎大流行的18个月内满足华莱士标准的患者。为了比较治疗对稳定缓解的作用，我们将患者分为三组：不进行全身治疗，仅使用甲氨蝶呤治疗和使用生物制剂治疗。结果纳入82例JIA患者，女性占68.3%，中位发病年龄4.49岁。JIA亚组间的缓解生存率无差异。近80%的患者在3年后保持缓解，5年后仍有很高比例的患者（68.3%）处于缓解状态。57名患者（69.5%）在新冠肺炎大流行的18个月内达到稳定缓解。未接受全身治疗的患者更有可能出现稳定缓解（47.4%）（p = 0.015）。结论：在现实生活条件下，缓解生存期是长期的，近80%的患者在3年后保持稳定的缓解。单用甲氨蝶呤治疗的患者更容易出现耀斑。

{"title":"Real life treatment in juvenile idiopathic arthritis: Is remission long lasting?","authors":"Laura Trives-Folguera, Ana Melissa Anzola, Indalecio Monteagudo-Saéz, Juan Carlos Nieto-González","doi":"10.1016/j.reumae.2025.501949","DOIUrl":"10.1016/j.reumae.2025.501949","url":null,"abstract":"<div><h3>Objectives</h3><div>Juvenile idiopathic arthritis (JIA) is a chronic inflammatory disease that can cause pediatric disability. Achieving stable remission is the main objective to avoid disability. We evaluated remission survival in a cohort of patients with JIA and analyzed factors that might influence long lasting remission.</div></div><div><h3>Methods</h3><div>We designed an observational, retrospective and longitudinal study of JIA patients. Remission survival was determined from the first visit in clinical remission to the first flare after remission or the last visit recorded at the end of the study. Stable remission was defined as patients fulfilling the Wallace criteria during 18 months of the Covid pandemic. To compare the role of treatment on stable remission, we divided patients into three groups: without systemic treatment, treated with methotrexate only and treated with biologics.</div></div><div><h3>Results</h3><div>We included 82 JIA patients, 68.3% of whom were female and the median age of disease onset was 4.49 years old. There were no differences in the remission survival rates between JIA subgroups. Nearly 80% had maintained remission at 3 years and a high proportion of patients (68.3%) were still in remission after 5 years. Fifty-seven patients (69.5%) reached stable remission throughout 18 months of the Covid-19 pandemic. Stable remission was more likely in patients without systemic treatment (47.4%) (<em>p</em>  <!-->0.015).</div></div><div><h3>Conclusions</h3><div>Remission survival was long-term in real life conditions, with nearly 80% of our patients maintaining stable remission after 3 years. Flares were more frequent in patients treated with methotrexate in monotherapy.</div></div>","PeriodicalId":94193,"journal":{"name":"Reumatologia clinica","volume":"21 8","pages":"Article 501949"},"PeriodicalIF":0.0,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145223484","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Improving fracture risk classification in Spain: A 10-year evaluation of a modified FRAX-based algorithm 改进西班牙骨折风险分类：改进的基于frax算法的10年评估

Reumatologia clinica

Pub Date : 2025-10-01 DOI: 10.1016/j.reumae.2025.501950

Carmen Gomez-Vaquero, Maribel Mora, Xavier González-Giménez, Carla Marco-Pascual, Pilar Medina, Maria Marta Bianchi, Pilar Santo, Joan M. Nolla

Objective

Osteoporotic fractures represent a significant clinical and public health burden. Although FRAX is widely used to estimate 10-year fracture risk, its Spanish version underestimates the probability of major osteoporotic fractures (MOF). This study assessed the performance of a modified FRAX-based algorithm, calibrated for the Spanish population, to stratify postmenopausal women into clinically meaningful risk categories.

Methods

We retrospectively followed 837 women (mean age 62 ± 9 years in 2008) referred for bone densitometry. All MOF over a 10-year period were recorded. Women were initially categorized as low risk (MOFR < 3.5%) or high risk (≥10%). Those with MOFR between 3.5% and 10% were reclassified as high risk if they had osteoporosis or if the recalculated MOFR including BMD was ≥7%.

Results

A total of 124 women experienced a MOF (66 vertebral, 39 distal forearm, 10 hip, 9 humerus). Initial risk classification identified 40% of women as low risk (fracture incidence: 9.4%, 95% CI: 6.2–12.5), 42% as intermediate (16.3%, 95% CI: 12.4–20.1), and 18% as high risk (23.5%, 95% CI: 16.7–30.3). After reclassification, 69% were considered low risk (11.0%, 95% CI: 8.4–13.5) and 31% high risk (23.2%, 95% CI: 18.1–28.3).

Conclusions

The proposed FRAX-based algorithm improves fracture risk classification in Spanish women and supports more rational use of bone densitometry and therapeutic interventions.

目的骨质疏松性骨折是严重的临床和公共卫生负担。尽管FRAX被广泛用于估计10年骨折风险，但其西班牙语版本低估了主要骨质疏松性骨折（MOF）的概率。本研究评估了一种改进的基于frax的算法的性能，该算法针对西班牙人群进行了校准，将绝经后妇女分为临床有意义的风险类别。方法回顾性随访837例骨密度测定妇女（2008年平均年龄62±9岁）。记录了10年期间的所有MOF。女性最初被分类为低风险（MOFR < 3.5%）或高风险（≥10%）。MOFR在3.5% - 10%之间的患者如果患有骨质疏松症或重新计算的MOFR包括BMD≥7%，则被重新归类为高风险。结果124例女性发生MOF（66例椎体，39例前臂远端，10例髋关节，9例肱骨）。初始风险分类确定40%的女性为低风险（骨折发生率：9.4%,95% CI: 6.2-12.5）， 42%为中等风险（16.3%,95% CI: 12.4-20.1）， 18%为高风险（23.5%,95% CI: 16.7-30.3）。重新分类后，69%为低风险（11.0%,95% CI: 8.4-13.5）， 31%为高风险（23.2%,95% CI: 18.1-28.3）。结论提出的基于frax的算法改善了西班牙女性骨折风险分类，支持更合理地使用骨密度测量和治疗干预措施。

{"title":"Improving fracture risk classification in Spain: A 10-year evaluation of a modified FRAX-based algorithm","authors":"Carmen Gomez-Vaquero, Maribel Mora, Xavier González-Giménez, Carla Marco-Pascual, Pilar Medina, Maria Marta Bianchi, Pilar Santo, Joan M. Nolla","doi":"10.1016/j.reumae.2025.501950","DOIUrl":"10.1016/j.reumae.2025.501950","url":null,"abstract":"<div><h3>Objective</h3><div>Osteoporotic fractures represent a significant clinical and public health burden. Although FRAX is widely used to estimate 10-year fracture risk, its Spanish version underestimates the probability of major osteoporotic fractures (MOF). This study assessed the performance of a modified FRAX-based algorithm, calibrated for the Spanish population, to stratify postmenopausal women into clinically meaningful risk categories.</div></div><div><h3>Methods</h3><div>We retrospectively followed 837 women (mean age 62±9 years in 2008) referred for bone densitometry. All MOF over a 10-year period were recorded. Women were initially categorized as low risk (MOFR<3.5%) or high risk (≥10%). Those with MOFR between 3.5% and 10% were reclassified as high risk if they had osteoporosis or if the recalculated MOFR including BMD was ≥7%.</div></div><div><h3>Results</h3><div>A total of 124 women experienced a MOF (66 vertebral, 39 distal forearm, 10 hip, 9 humerus). Initial risk classification identified 40% of women as low risk (fracture incidence: 9.4%, 95% CI: 6.2–12.5), 42% as intermediate (16.3%, 95% CI: 12.4–20.1), and 18% as high risk (23.5%, 95% CI: 16.7–30.3). After reclassification, 69% were considered low risk (11.0%, 95% CI: 8.4–13.5) and 31% high risk (23.2%, 95% CI: 18.1–28.3).</div></div><div><h3>Conclusions</h3><div>The proposed FRAX-based algorithm improves fracture risk classification in Spanish women and supports more rational use of bone densitometry and therapeutic interventions.</div></div>","PeriodicalId":94193,"journal":{"name":"Reumatologia clinica","volume":"21 8","pages":"Article 501950"},"PeriodicalIF":0.0,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145223509","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Spanish cross-cultural adaptation and psychometric validation of the graded chronic pain scale revised for fibromyalgia 纤维肌痛分级慢性疼痛量表修订后的西班牙跨文化适应和心理测量学验证

Reumatologia clinica

Pub Date : 2025-10-01 DOI: 10.1016/j.reumae.2025.501965

José Édgar Ferrández-Gómez , Mariano Gacto-Sánchez , Aitor Baño-Alcaraz

Background

Chronic widespread pain represents one of the cornerstones in the definition of fibromyalgia. Pain severity can be measured through different instruments, among which the Graded Chronic Pain Scale represents an outstanding framework to assess pain. Its revised version (GCPS-R) has been recently created to adhere to the new paradigmatic definition of chronic pain. Despite the relevance and clinical impact of the GCPS-R, its validation into Spanish has not been performed yet.

Objectives

To develop a cross-cultural Spanish-language adaptation of the GCPS-R in a sample of patients diagnosed with fibromyalgia. Besides, we aimed to carry out an initial psychometric analysis of the questionnaire in this population.

Methods

An observational, prospective, longitudinal study was conducted among a sample of subjects with fibromyalgia. The translation and cross-cultural adaptation of the GCPS-R was performed, and the new version of the instrument was administered to patients with fibromyalgia. Construct validity was assessed by means of factor analysis, whilst internal consistency, convergent validity, and test–retest reliability were also performed.

Results

The sample analyzed consisted of 224 subjects overall. Factor 1 displayed a Cronbach's alpha of 0.711, whilst Factor 2 had an alpha value of 0.890. The convergent validity analysis performed on the pain-intensity subscale of the instrument yielded statistically significant and strong correlation coefficients (Pearson's r = 0.713; p-value < 0.001). Test–retest reliability yielded weighted Cohen's Kappa scores of 0.537 (p-value < 0.001).

Conclusion

The GCPS-R-SP represents a simple, easy to administrate, and clinically efficient measure with favorable psychometric properties, covering the level and the impact of chronic pain in subjects with fibromyalgia.

背景：慢性广泛性疼痛是纤维肌痛定义的基础之一。疼痛的严重程度可以通过不同的工具来测量，其中慢性疼痛分级量表是评估疼痛的一个杰出的框架。它的修订版（GCPS-R）最近被创建，以坚持慢性疼痛的新范式定义。尽管GCPS-R具有相关性和临床影响，但其在西班牙语中的验证尚未进行。目的在诊断为纤维肌痛的患者样本中开发跨文化的西班牙语适应性GCPS-R。此外，我们的目的是对该人群的问卷进行初步的心理测量分析。方法对纤维肌痛患者进行一项观察性、前瞻性、纵向研究。对GCPS-R进行翻译和跨文化改编，并将新版仪器应用于纤维肌痛患者。构念效度采用因子分析评估，内部一致性、收敛效度和重测信度也进行了评估。结果分析样本共224人。因子1的α值为0.711，因子2的α值为0.890。对该工具的疼痛强度子量表进行的收敛效度分析产生了具有统计学意义的强相关系数（Pearson's r = 0.713； p值<； 0.001）。重测信度的加权Cohen's Kappa得分为0.537 （p值<； 0.001）。结论GCPS-R-SP是一种简单易行、临床有效的测量方法，具有良好的心理测量特性，涵盖了纤维肌痛患者慢性疼痛的水平及其影响。

{"title":"Spanish cross-cultural adaptation and psychometric validation of the graded chronic pain scale revised for fibromyalgia","authors":"José Édgar Ferrández-Gómez , Mariano Gacto-Sánchez , Aitor Baño-Alcaraz","doi":"10.1016/j.reumae.2025.501965","DOIUrl":"10.1016/j.reumae.2025.501965","url":null,"abstract":"<div><h3>Background</h3><div>Chronic widespread pain represents one of the cornerstones in the definition of fibromyalgia. Pain severity can be measured through different instruments, among which the Graded Chronic Pain Scale represents an outstanding framework to assess pain. Its revised version (GCPS-R) has been recently created to adhere to the new paradigmatic definition of chronic pain. Despite the relevance and clinical impact of the GCPS-R, its validation into Spanish has not been performed yet.</div></div><div><h3>Objectives</h3><div>To develop a cross-cultural Spanish-language adaptation of the GCPS-R in a sample of patients diagnosed with fibromyalgia. Besides, we aimed to carry out an initial psychometric analysis of the questionnaire in this population.</div></div><div><h3>Methods</h3><div>An observational, prospective, longitudinal study was conducted among a sample of subjects with fibromyalgia. The translation and cross-cultural adaptation of the GCPS-R was performed, and the new version of the instrument was administered to patients with fibromyalgia. Construct validity was assessed by means of factor analysis, whilst internal consistency, convergent validity, and test–retest reliability were also performed.</div></div><div><h3>Results</h3><div>The sample analyzed consisted of 224 subjects overall. Factor 1 displayed a Cronbach's alpha of 0.711, whilst Factor 2 had an alpha value of 0.890. The convergent validity analysis performed on the pain-intensity subscale of the instrument yielded statistically significant and strong correlation coefficients (Pearson's <em>r</em>      <!-->0.001).</div></div><div><h3>Conclusion</h3><div>The GCPS-R-SP represents a simple, easy to administrate, and clinically efficient measure with favorable psychometric properties, covering the level and the impact of chronic pain in subjects with fibromyalgia.</div></div>","PeriodicalId":94193,"journal":{"name":"Reumatologia clinica","volume":"21 8","pages":"Article 501965"},"PeriodicalIF":0.0,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145223511","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Establishing reference values for serum urate in healthy adults from Mexico City: Data from the Tlalpan 2020 cohort 建立墨西哥城健康成人血清尿酸的参考值：来自Tlalpan 2020队列的数据

Reumatologia clinica

Pub Date : 2025-10-01 DOI: 10.1016/j.reumae.2025.501943

Hilary Miranda-Mendoza , Daniel Paulino-González , Julio Sesma-Soto , Stephany Segura-García , Gerardo Tirado-Ojeda , Abraham Romero-Beltrán , Fernando Ortiz-Sanchez , Michele Enríquez-Luna , Brandon Fisher-Bautista , Guadalupe O. Gutiérrez-Esparza , Mireya Martínez-García , Luis M. Amezcua-Guerra

Background

Urate is the final product of purine catabolism, and its levels have been linked to various cardiometabolic disorders. In Mexico, most epidemiological data on urate levels derive from populations with existing comorbidities, limiting the establishment of normative reference values.

Objective

To characterize the distribution of serum urate concentrations in a healthy adult population residing in Mexico City.

Methods

A cross-sectional analysis was conducted using data from 3099 healthy adults (64.6% women) enrolled in the Tlalpan 2020 cohort. Participants with chronic diseases, abnormal blood pressure or glucose levels, or exposure to urate-altering medications were excluded. Clinical, anthropometric, and biochemical parameters were recorded, and serum urate concentrations were analyzed overall and stratified by sex.

Results

The median serum urate level in the overall cohort was 5.16 mg/dL (interquartile range, 4.32–6.15), with a central 95% reference interval ranging from 3.05 to 7.98 mg/dL. Median urate levels differed significantly by sex: 4.60 mg/dL (3.99–5.28) in women and 6.39 mg/dL (5.61–7.09) in men. The prevalence of hyperuricemia in the total cohort was 16.5%, notably higher in men (28.4%) compared to women (10.0%).

Conclusion

This study establishes sex-specific reference values for serum urate in a healthy Mexican adult population. The findings may inform clinical decision-making and future research on urate-related risk stratification.

尿酸是嘌呤分解代谢的最终产物，其水平与各种心脏代谢疾病有关。在墨西哥，大多数关于准确水平的流行病学数据来自已有合并症的人群，限制了规范性参考值的建立。目的了解墨西哥城健康成人血清尿酸浓度的分布特征。方法采用来自Tlalpan 2020队列的3099名健康成年人（64.6%为女性）的数据进行横断面分析。患有慢性疾病、血压或血糖水平异常或暴露于改变尿酸的药物的参与者被排除在外。记录临床、人体测量和生化参数，并按性别对血清尿酸浓度进行总体和分层分析。结果整个队列的血清尿酸水平中位数为5.16 mg/dL（四分位数范围为4.32 ~ 6.15），中心95%参考区间为3.05 ~ 7.98 mg/dL。中位尿酸水平因性别而有显著差异：女性为4.60 mg/dL(3.99-5.28)，男性为6.39 mg/dL（5.61-7.09）。在整个队列中，高尿酸血症的患病率为16.5%，男性（28.4%）明显高于女性（10.0%）。结论：本研究建立了墨西哥健康成人血清尿酸盐的性别特异性参考值。这些发现可能会为临床决策和未来的研究提供准确相关风险分层的信息。

{"title":"Establishing reference values for serum urate in healthy adults from Mexico City: Data from the Tlalpan 2020 cohort","authors":"Hilary Miranda-Mendoza , Daniel Paulino-González , Julio Sesma-Soto , Stephany Segura-García , Gerardo Tirado-Ojeda , Abraham Romero-Beltrán , Fernando Ortiz-Sanchez , Michele Enríquez-Luna , Brandon Fisher-Bautista , Guadalupe O. Gutiérrez-Esparza , Mireya Martínez-García , Luis M. Amezcua-Guerra","doi":"10.1016/j.reumae.2025.501943","DOIUrl":"10.1016/j.reumae.2025.501943","url":null,"abstract":"<div><h3>Background</h3><div>Urate is the final product of purine catabolism, and its levels have been linked to various cardiometabolic disorders. In Mexico, most epidemiological data on urate levels derive from populations with existing comorbidities, limiting the establishment of normative reference values.</div></div><div><h3>Objective</h3><div>To characterize the distribution of serum urate concentrations in a healthy adult population residing in Mexico City.</div></div><div><h3>Methods</h3><div>A cross-sectional analysis was conducted using data from 3099 healthy adults (64.6% women) enrolled in the Tlalpan 2020 cohort. Participants with chronic diseases, abnormal blood pressure or glucose levels, or exposure to urate-altering medications were excluded. Clinical, anthropometric, and biochemical parameters were recorded, and serum urate concentrations were analyzed overall and stratified by sex.</div></div><div><h3>Results</h3><div>The median serum urate level in the overall cohort was 5.16mg/dL (interquartile range, 4.32–6.15), with a central 95% reference interval ranging from 3.05 to 7.98mg/dL. Median urate levels differed significantly by sex: 4.60mg/dL (3.99–5.28) in women and 6.39mg/dL (5.61–7.09) in men. The prevalence of hyperuricemia in the total cohort was 16.5%, notably higher in men (28.4%) compared to women (10.0%).</div></div><div><h3>Conclusion</h3><div>This study establishes sex-specific reference values for serum urate in a healthy Mexican adult population. The findings may inform clinical decision-making and future research on urate-related risk stratification.</div></div>","PeriodicalId":94193,"journal":{"name":"Reumatologia clinica","volume":"21 8","pages":"Article 501943"},"PeriodicalIF":0.0,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145223510","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Associated factors to health-related quality of life in anti-neutrophil cytoplasmic antibodies-associated vasculitis patients: Data from the Almenara Vasculitis Cohort 抗中性粒细胞细胞质抗体相关血管炎患者健康相关生活质量的相关因素：来自Almenara血管炎队列的数据

Reumatologia clinica

Pub Date : 2025-08-01 DOI: 10.1016/j.reumae.2025.501942

Allison Milagros Figueroa-Sánchez , Leonor Stefani León-Yaurimucha , Manuel F. Ugarte-Gil , Victor R. Pimentel-Quiroz

Objective

To determine the factors associated with health-related quality of life (HRQoL) in adult patients with ANCA-associated vasculitis (AAV).

Methodology

An observational, analytical, retrospective study was conducted using a convenience sampling technique. Data were obtained from the Almenara Vasculitis Cohort during the period from December 2022 to December 2023. Sociodemographic and disease-related features were obtained using a data collection form. Disease activity, damage accrual, and HRQoL were assessed using the BVASv3, VDI, and SF-36 questionnaires, respectively. Cross-sectional univariable and multivariable linear regression models were performed. Multivariate models were generated using a backward selection procedure with an alpha to stay in the model of 0.05.

Results

Fifty-five patients were evaluated; 41 (74.6%) of them were female. Their mean age and disease duration were 58.7 (13.5) and 5.8 (5.2) years, respectively. In the multivariate analysis, low socioeconomic status, older age, and higher erythrocyte sedimentation rate (ESR) were associated with worse HRQoL. Conversely, male sex, have a diagnosis of eosinophilic granulomatosis with polyangiitis (EGPA), have an employment, and the use of immunosuppressive (IS) drugs other than cyclophosphamide or rituximab were associated with better HRQoL.

Conclusions

In our study, male sex, have an employment, the EGPA subtype, and treatment with IS other than rituximab and cyclophosphamide were associated with better HRQoL. Meanwhile, older age, low socioeconomic status, and high ESR levels were associated with worse HRQoL.

目的：探讨成人anca相关性血管炎（AAV）患者健康相关生活质量（HRQoL）的相关因素。方法：采用方便抽样技术进行观察性、分析性、回顾性研究。数据来自2022年12月至2023年12月期间的Almenara血管炎队列。使用数据收集表获得社会人口学和疾病相关特征。分别使用BVASv3、VDI和SF-36问卷评估疾病活动性、损害累积和HRQoL。采用截面单变量和多变量线性回归模型。使用反向选择程序生成多变量模型，alpha保持在0.05的模型中。结果：共评估55例患者；其中女性41例（74.6%）。平均年龄58.7（13.5）岁，病程5.8（5.2）岁。在多变量分析中，低社会经济地位、年龄较大和较高的红细胞沉降率（ESR）与较差的HRQoL相关。相反，男性，诊断为嗜酸性肉芽肿病合并多血管炎（EGPA），有工作，使用除环磷酰胺或利妥昔单抗外的免疫抑制（IS）药物与较好的HRQoL相关。结论：在我们的研究中，男性、有工作、EGPA亚型以及使用非利妥昔单抗和环磷酰胺的IS治疗与较好的HRQoL相关。同时，年龄较大、社会经济地位低、ESR水平高与HRQoL较差相关。

{"title":"Associated factors to health-related quality of life in anti-neutrophil cytoplasmic antibodies-associated vasculitis patients: Data from the Almenara Vasculitis Cohort","authors":"Allison Milagros Figueroa-Sánchez , Leonor Stefani León-Yaurimucha , Manuel F. Ugarte-Gil , Victor R. Pimentel-Quiroz","doi":"10.1016/j.reumae.2025.501942","DOIUrl":"10.1016/j.reumae.2025.501942","url":null,"abstract":"<div><h3>Objective</h3><div>To determine the factors associated with health-related quality of life (HRQoL) in adult patients with ANCA-associated vasculitis (AAV).</div></div><div><h3>Methodology</h3><div>An observational, analytical, retrospective study was conducted using a convenience sampling technique. Data were obtained from the Almenara Vasculitis Cohort during the period from December 2022 to December 2023. Sociodemographic and disease-related features were obtained using a data collection form. Disease activity, damage accrual, and HRQoL were assessed using the BVASv3, VDI, and SF-36 questionnaires, respectively. Cross-sectional univariable and multivariable linear regression models were performed. Multivariate models were generated using a backward selection procedure with an alpha to stay in the model of 0.05.</div></div><div><h3>Results</h3><div>Fifty-five patients were evaluated; 41 (74.6%) of them were female. Their mean age and disease duration were 58.7 (13.5) and 5.8 (5.2) years, respectively. In the multivariate analysis, low socioeconomic status, older age, and higher erythrocyte sedimentation rate (ESR) were associated with worse HRQoL. Conversely, male sex, have a diagnosis of eosinophilic granulomatosis with polyangiitis (EGPA), have an employment, and the use of immunosuppressive (IS) drugs other than cyclophosphamide or rituximab were associated with better HRQoL.</div></div><div><h3>Conclusions</h3><div>In our study, male sex, have an employment, the EGPA subtype, and treatment with IS other than rituximab and cyclophosphamide were associated with better HRQoL. Meanwhile, older age, low socioeconomic status, and high ESR levels were associated with worse HRQoL.</div></div>","PeriodicalId":94193,"journal":{"name":"Reumatologia clinica","volume":"21 7","pages":"Article 501942"},"PeriodicalIF":0.0,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144984517","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Anti-MDA5 antibody dermatomyositis: PET findings of early interstitial lung disease 抗mda5抗体皮肌炎：早期间质性肺病的PET表现

Reumatologia clinica

Pub Date : 2025-08-01 DOI: 10.1016/j.reumae.2025.501919

Wan-Hao Tsai , Chiehyu Shen

引用次数: 0